RLAY - Relay Therapeutics Inc Stock Price, Fair Value and News

$4.66-0.14 (-2.92%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RLAY Price Action

Last 7 days

-19.8%

Last 30 days

-27.5%

Last 90 days

-32.8%

Trailing 12 Months

-41.5%

RLAY RSI Chart

RLAY Valuation

Market Cap

780.0M

Price/Earnings (Trailing)

-2.26

Price/Sales (Trailing)

32.8

Price/Free Cashflow

-2.76

RLAY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RLAY Fundamentals

RLAY Revenue

Revenue (TTM)

23.8M

Rev. Growth (Yr)

-67.17%

Rev. Growth (Qtr)

-100%

RLAY Earnings

Earnings (TTM)

-345.2M

Earnings Growth (Yr)

-34.03%

Earnings Growth (Qtr)

4.45%

RLAY Profitability

Return on Equity

-41.15%

Return on Assets

-37.11%

Free Cashflow Yield

-36.23%

RLAY Investor Care

Shares Dilution (1Y)

35.79%

Diluted EPS (TTM)

-2.6

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	35.9M	40.7M	23.8M	0
2023	8.8M	16.2M	23.6M	31.0M
2022	2.0M	2.1M	2.3M	9.2M
2021	62.2M	41.7M	21.3M	830.0K
2020	0	7.2M	5.3M	82.7M
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
WEBSITE	relaytx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	345

Relay Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Relay Therapeutics Inc? What does RLAY stand for in stocks?

RLAY is the stock ticker symbol of Relay Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Relay Therapeutics Inc (RLAY)?

As of Wed Nov 20 2024, market cap of Relay Therapeutics Inc is 780 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RLAY stock?

You can check RLAY's fair value in chart for subscribers.

Is Relay Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RLAY is over valued or under valued. Whether Relay Therapeutics Inc is cheap or expensive depends on the assumptions which impact Relay Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RLAY.

What is Relay Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, RLAY's PE ratio (Price to Earnings) is -2.26 and Price to Sales (PS) ratio is 32.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLAY PE ratio will change depending on the future growth rate expectations of investors.